Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab in Recurrent/Metastatic Head and Neck Cancers
NCT05063552Phase 3Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Mar 2023
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of bevacizumab, atezolizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by National Cancer Institute. Started Mar 2023; status: active, not recruiting.
02
Drugs
bevacizumabatezolizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05063552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05063552.